Brad Moriyama

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
    Pharmacotherapy 33:e19-22. 2013
  2. pmc Pharmacokinetics of liposomal amphotericin B in pleural fluid
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 54:1633-5. 2010
  3. pmc High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients
    Brad Moriyama
    National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD 20892, USA
    Ann Pharmacother 44:929-35. 2010
  4. pmc Accelerated metabolism of voriconazole and its partial reversal by cimetidine
    Brad Moriyama
    NIH Clinical Center Pharmacy Dept, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 53:1712-4. 2009
  5. pmc Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, National Heart Lung and Blood Instititute, Bethesda, MD, USA
    Antimicrob Agents Chemother 55:2478-80. 2011
  6. doi request reprint Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA
    Ann Pharmacother 43:1324-37. 2009
  7. pmc Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, Bethesda, MD, USA
    Mycoses 55:290-7. 2012
  8. doi request reprint The postantifungal and paradoxical effects of echinocandins against Candida spp
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, Bethesda, MD, USA
    Future Microbiol 7:565-9. 2012
  9. pmc Physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution
    Brad Moriyama
    Pharmacy Department, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Am J Health Syst Pharm 67:562-5. 2010

Detail Information

Publications9

  1. pmc Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
    Pharmacotherapy 33:e19-22. 2013
    ..If an obese patient dosed on total body weight is also a CYP2C19 poor metabolizer, serum voriconazole concentrations will be further elevated, potentially leading to drug-induced toxicity...
  2. pmc Pharmacokinetics of liposomal amphotericin B in pleural fluid
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 54:1633-5. 2010
    ..4%, with pleural fluid concentrations of 2.12 to 4.91 microg/ml. Given the relatively low level of intrapleural penetration of liposomal amphotericin B, chest tube drainage may be warranted for successful treatment of zygomycotic empyema...
  3. pmc High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients
    Brad Moriyama
    National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD 20892, USA
    Ann Pharmacother 44:929-35. 2010
    ..To report a case series of high-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections...
  4. pmc Accelerated metabolism of voriconazole and its partial reversal by cimetidine
    Brad Moriyama
    NIH Clinical Center Pharmacy Dept, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 53:1712-4. 2009
    ..Target voriconazole levels were restored with high dosages of voriconazole (up to 40 mg/kg of body weight/day) and the addition of cimetidine as a cytochrome P450 enzyme inhibitor...
  5. pmc Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, National Heart Lung and Blood Instititute, Bethesda, MD, USA
    Antimicrob Agents Chemother 55:2478-80. 2011
    ..125 (12.5%), with pleural fluid concentrations ranging between 0.67 and 0.88 μg/ml...
  6. doi request reprint Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA
    Ann Pharmacother 43:1324-37. 2009
    ..To describe the rationale, principles, and dosage calculations for continuous-infusion beta-lactam antibiotics to treat multidrug-resistant bacteria in patients undergoing continuous venovenous hemofiltration (CVVH)...
  7. pmc Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, Bethesda, MD, USA
    Mycoses 55:290-7. 2012
    ..Recovery from these ADIs occurred in 80.6% of patients. We recommend using alternative antifungal agents if possible in patients receiving vincristine to avoid this serious and potentially life-threatening drug interaction...
  8. doi request reprint The postantifungal and paradoxical effects of echinocandins against Candida spp
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, Bethesda, MD, USA
    Future Microbiol 7:565-9. 2012
    ..The report by Shields et al. illustrates that short exposures to an echinocandin may lead to prolonged postantifungal effects and furthers our understanding of the paradoxical effect in C. albicans...
  9. pmc Physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution
    Brad Moriyama
    Pharmacy Department, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Am J Health Syst Pharm 67:562-5. 2010
    ..The physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution was assessed...